- Previous Close
1.0400 - Open
1.0600 - Bid 1.0020 x --
- Ask 1.0300 x --
- Day's Range
1.0002 - 1.0600 - 52 Week Range
0.7203 - 6.0000 - Volume
60,516 - Avg. Volume
56,036 - Market Cap (intraday)
80.298M - Beta (5Y Monthly) 1.18
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5200 - Earnings Date Feb 21, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Bio-Works Technologies AB (publ), a biotechnology company, engages in the research, development, manufacture, and supply of agarose-based separation products to purify proteins, enzymes, antibodies, peptides, and other biomolecules primarily in Sweden. It offers activated and affinity resins; hydrophobic interaction chromatography resins; GoBio Mini columns; immobilized metal-ion affinity chromatography resins; ion exchange resins; desalting columns; RoboColumns and Optimo PRO 96 well screens; screening kits; and size exclusion chromatography resins. The company's products are used in antibodies, his-tagged proteins, proteins, peptides, oligonucleotides, and viruses and vaccines applications. Bio-Works Technologies AB (publ) founded in 2006 and is headquartered in Uppsala, Sweden.
www.bio-works.comRecent News: BIOWKS.ST
View MorePerformance Overview: BIOWKS.ST
Trailing total returns as of 2/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIOWKS.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIOWKS.ST
View MoreValuation Measures
Market Cap
80.30M
Enterprise Value
32.44M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.48
Price/Book (mrq)
1.39
Enterprise Value/Revenue
0.86
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-99.05%
Return on Assets (ttm)
-36.04%
Return on Equity (ttm)
-73.81%
Revenue (ttm)
37.88M
Net Income Avi to Common (ttm)
-37.52M
Diluted EPS (ttm)
-0.5200
Balance Sheet and Cash Flow
Total Cash (mrq)
47.86M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-28.75M